Anti-FcRL5/CD3 TDB (BFCR4350A) induced mild/moderate cytokine release immediately after administration in primates, effectively killing myeloma cells and marrow plasma cells, but the effect in mouse models was significantly limited [131]. The gene discussed is FCRL5; the disease is plasma cell myeloma.